.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Healthtrust
Moodys
Colorcon
Cipla
Dow
Fuji
Citi
Novartis

Generated: June 28, 2017

DrugPatentWatch Database Preview

Solifenacin succinate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for solifenacin succinate and what is the scope of solifenacin succinate patent protection?

Solifenacin succinate
is the generic ingredient in two branded drugs marketed by Astellas and Teva Pharms Usa, and is included in two NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Solifenacin succinate has thirty-one patent family members in twenty-two countries.

There are twenty-nine drug master file entries for solifenacin succinate. Three suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: solifenacin succinate

Tradenames:2
Patents:2
Applicants:2
NDAs:2
Drug Master File Entries: see list29
Suppliers / Packagers: see list3
Bulk Api Vendors: see list68
Clinical Trials: see list232
Patent Applications: see list1,828
Therapeutic Class:Genitourinary Agents
Drug Prices:see low prices
DailyMed Link:solifenacin succinate at DailyMed

Pharmacology for Ingredient: solifenacin succinate

Tentative approvals for SOLIFENACIN SUCCINATE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe5MGTABLET;ORAL
► Subscribe► Subscribe10MGTABLET;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa
SOLIFENACIN SUCCINATE
solifenacin succinate
TABLET;ORAL091464-001Apr 2, 2014ABRXNoNo► Subscribe► Subscribe
Teva Pharms Usa
SOLIFENACIN SUCCINATE
solifenacin succinate
TABLET;ORAL091464-002Apr 2, 2014ABRXNoNo► Subscribe► Subscribe
Astellas
VESICARE
solifenacin succinate
TABLET;ORAL021518-002Nov 19, 2004ABRXYesYes6,017,927► SubscribeYY ► Subscribe
Astellas
VESICARE
solifenacin succinate
TABLET;ORAL021518-001Nov 19, 2004ABRXYesNo6,017,927► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: solifenacin succinate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,174,896 Quinuclidine derivatives and medicinal composition thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: solifenacin succinate

Country Document Number Estimated Expiration
Poland321019► Subscribe
South Korea100386487► Subscribe
Mexico9704880► Subscribe
Taiwan305842► Subscribe
Australia4355396► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SOLIFENACIN SUCCINATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
133Luxembourg► Subscribe91133, EXPIRES: 20181118
2004 00037Denmark► Subscribe
C/GB04/029United Kingdom► SubscribePRODUCT NAME: SOLIFENACIN AND/OR PHARMACEUTICALLY ACTIVE SALT THEREOF; REGISTERED: NL RVG 29151 20031216; NL RVG 29152 20031216; UK PL 00166/0197 20040816; UK PL 0016/0198 20040816
C014/2004Ireland► SubscribeSPC014/2004: 20050803, EXPIRES: 20181215
C0032France► SubscribePRODUCT NAME: SUCCINATE DE SOLIFENACINE; NAT. REGISTRATION NO/DATE: NL 30 109 20040816; FIRST REGISTRATION: NL - RVG 29 151 20031216
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Teva
Novartis
UBS
McKinsey
Farmers Insurance
US Department of Justice
Cerilliant
Dow
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot